Stability Testing Strategy During Biologic Technology Transfer
Biologic drugs are sensitive to environmental, equipment, and procedural changes. Even slight variations during transfer can impact:
Click to read the full article.
Stability Testing for Biopharmaceuticals
Real-Time Stability Monitoring and Data Trending in Biologics
Biologics are sensitive to subtle environmental and formulation changes that may cause:
Click to read the full article.
Stability Testing for Cell and Gene Therapy Products
Stability studies ensure that a CGT product maintains its identity, purity, potency, and safety from the point of manufacture to the point of administration. These studies help determine:
Click to read the full article.
Stability Testing for Lyophilized Biologics
Many biologics—such as monoclonal antibodies, peptides, vaccines, and enzymes—are inherently unstable in liquid form. Lyophilization provides the following benefits:
Click to read the full article.
Regulatory Expectations for Stability Testing of Biosimilars
Biosimilars are highly similar but not identical to innovator biologics. As such, they must demonstrate:
Click to read the full article.
Stress Testing Strategies for Biopharmaceuticals
Stress testing serves several key objectives in product development and regulatory compliance:
Click to read the full article.
Freeze-Thaw Stability Evaluation of Biologics
Biologic products—especially proteins and monoclonal antibodies—are sensitive to temperature fluctuations. Freezing and thawing can induce:
Click to read the full article.
Photostability Testing of Biopharmaceutical Products
Biopharmaceuticals such as monoclonal antibodies, peptides, and protein-based vaccines contain amino acids like tryptophan, tyrosine, and phenylalanine, which absorb UV light and are prone to photodegradation. Exposure to light can cause:
Click to read the full article.
Container Closure Integrity Testing in Biologic Stability Studies
Biologics, including monoclonal antibodies, vaccines, and recombinant proteins, are highly sensitive to environmental contaminants such as oxygen, moisture, and microbes. CCI failures can lead to:
Click to read the full article.
Impact of Packaging Systems on Biologic Stability
Unlike small-molecule drugs, biologics—such as monoclonal antibodies, peptides, and fusion proteins—are macromolecules with complex structures. They are prone to degradation via aggregation, denaturation, oxidation, and adsorption. Packaging systems must:
Click to read the full article.